REQUEST A DEMO
Total
USD $0.00
Search more companies

Janssen Cilag S A (Colombia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Janssen Cilag S A Profile Updated: September 17, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Spanish Download a sample report

Janssen Cilag S.A. is a pharmaceutical Company, subsidiary of Johnson & Johnson, born in 1983. The company has 5 specialized lines of work: Central Nervous System, Primary Care, Oncology/Pain, Infectious Immunology and Infectology/Antibiotics. Among its products are Caelyx, Concerta and Dacogen. It has operations in Colombia, Peru and Ecuador through the Cluster L.A. North

Headquarters
Avenida Calle 26 # 69-76 Edificio Elemento, Torre 2, Piso 7 y Piso 10 Consultorio 1
Bogota D.C.; Bogota D.C; Postal Code: 0902

Contact Details: Purchase the Janssen Cilag S A report to view the information.

Basic Information
Total Employees:
Purchase the Janssen Cilag S A report to view the information.
Outstanding Shares:
Purchase the Janssen Cilag S A report to view the information.
Registered Capital:
Purchase the Janssen Cilag S A report to view the information.
Incorporation Date:
January 12, 1983
Key Executives
Purchase this report to view the information.
Legal Representative
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Deputy Member of the Board of Directors
Purchase this report to view the information.
Deputy Member of the Board of Directors
Ownership Details
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Janssen Cilag S A report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency COP. Absolute financial data is included in the purchased report.
Net sales revenue
18.81%
Total operating revenue
19.23%
Operating profit (EBIT)
-7.43%
Net Profit (Loss) for the Period
1.81%
Total assets
24.2%
Total equity
24.58%
Operating Profit Margin (ROS)
-1.72%
Net Profit Margin
-0.71%
Return on Equity (ROE)
-3.2%
Quick Ratio
0.64%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?